OncRef

Clinical Trial: NCT05753618

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

Status:

RECRUITING

Phase:

Phase 4

Lead Sponsor:Ottawa Hospital Research Institute
Information Provided By:Ottawa Hospital Research Institute
Last Update Posted:2026-07-08

Study Overview

Brief Summary

The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.

Official Title

A Randomized Pragmatic Trial Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy (REaCT-OGF)

Conditions

Early-stage Breast Cancer

Intervention / Treatment

  • Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
  • Drug: Omission of Granulocyte Colony-Stimulating Factor (G-CSF)

Other Study ID Numbers

  • REaCT-OGF

Start Date (Actual)

2023-04-17

Primary Completion Date (Estimated)

2026-10

Study Completion Date (Estimated)

2026-10

Enrollment (Estimated)

242

Study Type

Interventional

Phase

Phase 4